Kidney and Pancreas Transplant Program, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Curr Opin Organ Transplant. 2008 Aug;13(4):386-94. doi: 10.1097/MOT.0b013e3283097476.
There is an ongoing vigorous debate regarding the wisdom of the current prohibition of organ sales in the United States. We argue that this prohibition must remain in place. We discuss the current international realities regarding organ vending in order to show that even a so-called 'regulated' market brings with it danger to the welfare of transplant donors, their recipients, and potential recipients of nonrenal organs. We counter the specific arguments made in favor of organ sales while recommending multiple measures that can serve to remove disincentives to noncommercial organ donation. We encourage the investment in innovative healthy transplant practice for the benefit of all.
In 'natural experiments' performed in developing countries the outcome for kidney vendors, in terms of both their medical and psychosocial health, has been shown to be poor. A high incidence of serious infections has been reported in recipients of vended organs.
Commercialization of living kidney donation does not serve the interests of the donors, endangers the health of recipients, and undermines the healthy development of the international transplant endeavor.
目的综述：目前美国禁止器官买卖，对此存在激烈的争论。我们认为这一禁令必须继续保留。我们讨论了当前国际上器官买卖的实际情况，以表明即使是所谓的“有监管”的市场，也会给器官捐献者及其接受者以及潜在的非肾器官接受者的福利带来危险。我们反驳了支持器官买卖的具体论点，并同时推荐了多种可以消除非商业性器官捐献障碍的措施。我们鼓励投资创新的健康移植实践，造福所有人。
最近发现：在发展中国家进行的“自然实验”中，肾脏买卖者的健康状况，无论是身体上还是心理上，都很差。据报道，接受出售器官的患者有很高的严重感染发生率。
总结：活体肾脏捐赠的商业化既不符合捐赠者的利益，也会危及接受者的健康，并破坏国际器官移植事业的健康发展。
